ArticleEuropean journal of hospital pharmacy : science and practice2021

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Loma Al-Mansouri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.